[9]Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015 Aug 26;7(302):302ra136.Rudin CM, Reck M, Johnson ML, Blackhall F, Hann CL, Yang JC, Bailis J...
在SCLC中，促进DLL3表达，DLL3与Notch1受体结合，将抑制Notch信号活化，Notch信号靶基因HES1、HEY1的表达下调，对肿瘤的抑制解除，促进SCLC的发生发展 [9]；DLL3/Notch2可以增加细胞周期蛋白CyclinD1和CyclinD3的表达，提示DLL3/Notch2可能通过上调CyclinD1和CyclinD3蛋白促进SCLC细胞的增殖 [10]。此外DLL3和Notch...
[6] Saunders, Laura R., et al. "A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo." Science translational medicine 7.302 (2015): 302ra136-302ra136. [7] Stanley, Pamela. "Regulation of Notch signaling by glycosylation." Curren...
相比之下,DLL3在正常组织中的表达很大程度上局限于细胞胞内的膜上,尤其是高尔基体[1]。目前,临床前和临床环境中都在研究针对DLL3的各种策略。这些策略包括探索抗体-药物偶联物(ADC)、T细胞接合分子以及基于CAR的疗法。特司林-洛伐妥珠...
[1]. Saunders LR, Bankovich AJ, Anderson WC, et al: A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 7:302ra136, 2015 [2]. Tanaka K, Isse K, Fujihira T, et al: Prevalence of Delta-like protein 3 ex...
[6] Saunders, Laura R., et al. "A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo." Science translational medicine 7.302 (2015): 302ra136-302ra136. [7] Stanley, Pamela. "Regulation of Notch signaling by glycosylation." Curren...
[1]. Saunders LR, Bankovich AJ, Anderson WC, et al: A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 7:302ra136, 2015 [2]. Tanaka K, Isse K, Fujihira T, et al: Prevalence of Delta-like protein 3 ex...
Delta-like protein 3 (DLL3) is a novel and tractable tumor-initiating cell-associated target for the antibody-drug conjugate SC16LD6.5 in high-grade pulmonary neuroendocrine tumors. Elevated expression of DLL3, an inhibitor of Notch pathway activation, marks the second recent observation that ...
Learn how investigational DLL3 and T-cell engager technology together have the potential to address unmet needs in SCLC and high-grade neuroendocrine cancers.
Member:GetGrade作用:等级判定(一般稀有史诗传说远古)Type:AttributePotentialDescriptorMember:GetMean作用:随机装备属性Type:DifficultyLevelMeasurementMember:GetStarChance作用:装备星辰率Type:GemGeneratorBaseMember:GetRandomCoeff作用:随机宝石属性Type:UnitGrowthProfileMember:GetRandomAttributeValue作用:升级英雄的属性随机Type...